TABLE 3.
Descriptive statistics on clinicopathological variables at enrolment for CKD cats in this prospective imaging study, grouped according to the detection of nephrocalcinosis by ultrasonography (“Absence of nephrocalcinosis” vs “Presence of nephrocalcinosis”).
| Variables (reference interval) | Absence of nephrocalcinosis (n = 14) | Presence of nephrocalcinosis (n = 22) | P‐value | ||
|---|---|---|---|---|---|
| Median [25th, 75th percentile] | n | Median [25th, 75th percentile] | n | ||
| Total calcium (8.2‐11.8 mg/dL) | 9.86 [9.77, 10.06] | 14 | 10.74 [10.08, 11.16] | 22 | .01 |
| Ionized calcium (4.76‐5.48 mg/dL) | 5.30 [5.25, 5.44] | 14 | 5.62 [5.30, 5.81] | 22 | .08 |
| Age (years) | 15.1 [13.5, 16.7] | 14 | 14.1 [12.5, 16.4] | 22 | .22 |
| BCS (“1‐3,” “4‐6,” “7‐9,” n [%]) | 4 [29], 10 [71], 0 [0] | 14 | 8 [36], 13 [59], 1 [5] | 22 | .83 |
| MCS (“0,” “1,” “2,” “3,” n [%]) | 1 [7], 3 [21], 10 [71], 0 [0] | 14 | 2 [10], 4 [19], 14 [67], 1 [5] | 21 | 1 |
| Weight (kg) | 3.2 [3.1, 3.7] | 14 | 3.8 [3.3, 4.4] | 22 | .13 |
| Sex (female neutered, n [%]) | 8 [57] | 14 | 10 [45] | 22 | .49 |
| Albumin (2.5‐4.5 g/dL) | 2.9 [2.8, 3.1] | 14 | 3.1 [3.0, 3.3] | 22 | .03 |
| ALP (≤ 60 U/L) | 26 [20, 34] | 14 | 24 [20, 30] | 22 | .66 |
| ALT (5‐60 U/L) | 43 [32, 49] | 14 | 52 [42, 64] | 22 | .03 |
| CaPP (<70 mg2/dL2) | 34.9 [32.8, 39.8] | 14 | 42.8 [38.1, 53.2] | 22 | .01 |
| Chloride (100‐124 mEq/L) | 117 [115, 118] | 7 | 121 [118125] | 8 | .07 |
| Creatinine (0.23‐2 mg/dL) | 2.27 [2.05, 2.48] | 14 | 2.60 [2.08, 3.09] | 22 | .14 |
| FGF23 a (56‐700 pg/mL) | 383 [265, 657] | 12 | 776 [289, 1988] | 21 | .06 |
| Glucose (54‐117 mg/dL) | 117 [97, 141] | 14 | 110 [93, 124] | 22 | .16 |
| Venous HCO3 − (17‐24 mmol/L) | 21.9 [19.8, 23.0] | 14 | 21.0 [18.8, 22.6] | 22 | .4 |
| Hypertension (controlled) (n [%]) | 2 [14] | 14 | 2 [9] | 22 | .63 |
| PCV (30‐45%) | 34 [32, 37] | 14 | 31 [28, 35] | 22 | .13 |
| Venous pH (7.21‐7.44) | 7.38 [7.35, 7.4] | 14 | 7.37 [7.30, 7.38] | 22 | .24 |
| Phosphate (2.79‐6.81 mg/dL) | 3.55 [3.20, 3.95] | 14 | 4.06 [3.72, 4.68] | 22 | .06 |
| Potassium (3.5‐5.5 mmol/L) | 3.5 [3.4, 4] | 14 | 3.9 [3.6, 4.2] | 22 | .15 |
| PTH a (2.6‐17.6 pg/mL) | 8.9 [5.0, 18.5] | 11 | 15.8 [4.3, 55.7] | 20 | .54 |
| SBP (<160 mm Hg) | 126 [120, 149] | 14 | 124 [120, 138] | 22 | .35 |
| SDMA (1‐14 μg/dL) | 18 [14, 20] | 14 | 20 [15, 25] | 22 | .3 |
| Sodium (145‐157 mEq/L) | 152 [149, 152] | 14 | 151 [149, 152] | 22 | .88 |
| Total magnesium (1.73‐2.57 mg/dL) | 1.93 [1.85, 2.08] | 14 | 2.15 [1.88, 2.40] | 22 | .02 |
| Total protein (6.0‐8.0 g/dL) | 7.9 [7.4, 8.5] | 14 | 7.4 [7.2, 8.2] | 22 | .23 |
| Urea (7.0‐27.7 mg/dL) | 41.2 [31.9, 45.1] | 7 | 49.4 [46.7, 53.6] | 8 | .06 |
| USG (≥1.035) | 1.016 [1.015, 1.018] | 11 | 1.016 [1.016, 1.019] | 12 | .38 |
| Urine pH | 6 [5, 7] | 11 | 6 [5, 6] | 12 | .49 |
| CKD duration (days) | 71 [38, 152] | 14 | 106 [71, 688] | 22 | .17 |
Note: Significant difference between groups (P ≤ .05) are highlighted in bold.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; BCS, body condition score; CaPP, calcium phosphate product; FGF23, fibroblast growth factor‐23; HCO3 −, bicarbonate; MCS, muscle condition score; n, number of cats; PCV, packed cell volume; PTH, parathyroid hormone; SBP, systolic blood pressure; SDMA, symmetric dimethylarginine; USG, urine specific gravity.
Baseline FGF23 and PTH were log‐transformed for comparison using independent samples t test.